Zobrazeno 1 - 10
of 119
pro vyhledávání: ''
Autor:
P. Andrew Futreal, Ken Furudate, Marina Konopleva, Sanam Loghavi, Guillermo Garcia-Manero, Sa A. Wang, Yuya Sasaki, Gheath Alatrash, Musa Yilmaz, Koji Sasaki, Naveen Pemmaraju, Latasha Little, Tapan M. Kadia, Koichi Takahashi, Farhad Ravandi, Kiyomi Morita, Curtis Gumbs, Jairo Matthews, Feng Wang, Hagop M. Kantarjian, Courtney D. DiNardo, Richard E. Champlin, Naval Daver, Tomoyuki Tanaka
Publikováno v:
Blood
Introduction While clonal hematopoiesis (CH) can precede the development of AML, preleukemic CH can persist after attaining remission. In rare cases, non-leukemic CH can also emerge after remission. Long-term clonal dynamics of persistent CH or emerg
Autor:
Su Young Kim, Ruby Nandam, Brenda Chyla, Shuo Ma, John Pesko, John F. Seymour, Ahmed Salem, Amanda Jacobson, Michael Y. Choi, Thomas J. Kipps, Andrew W. Roberts, Abdullah A. Masud, Mary Ann Anderson, Jennifer Arzt, Danielle M. Brander, Kathryn Humphrey
Publikováno v:
Blood
We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy. Patients received venetoclax daily (2
Autor:
Michel Attal, Xavier Leleu, Salomon Manier, Lotfi Benboubker, Clara Mariette, Cécile Sonntag, Karim Belhadj, Denis Caillot, Cyrille Touzeau, Martine Escoffre-Barbe, Benjamin Hebraud, Laurent Garderet, Soraya Wuilleme, Philippe Moreau, Jill Corre, Valérie Lauwers-Cances, Thierry Facon, Jehan Dupuis, Murielle Roussel
Publikováno v:
Blood. 138:113-121
Bortezomib, lenalidomide, and dexamethasone plus transplant is a standard of care for eligible patients with multiple myeloma. Because responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In
Autor:
Bianca Rocca, Francesca Palandri, Giovanna Petrucci, Chiara Paoli, Cristina Bucelli, Benedetta Porro, Nicola Vianelli, Francesco Rodeghiero, Elena Rossi, Alessandra Iurlo, Carlo Patrono, Irene Bertozzi, Alessandro M. Vannucchi, Maria Luigia Randi, Andrea Timillero, Monica Carpenedo, Mauro Di Ianni, Giuseppe Carli, Alfredo Dragani, Silvia Betti, Denise Soldati, Elena Maria Elli, Eloise Beggiato, Valerio De Stefano, Daniele Cattaneo, Giuseppe Lanzarone, Alberto Tosetto, Viviana Cavalca, Marco Ruggeri, Giorgina Specchia, Alessandra Ricco, Paola Ranalli
Publikováno v:
Blood. 136:171-182
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic regimen, but accelerated platelet generation may reduce the duration of platelet
Autor:
Christoffer Flensburg, Piers Blombery, David C.S. Huang, Huaxian Ma, Giovanna Pomilio, Sarah MacRaild, Sanam Loghavi, Rachel Thijssen, Fiona C. Brown, Ian J. Majewski, Jessica M. Salmon, Ing Soo Tiong, Hagop M. Kantarjian, Adam Ivey, Xufeng Chen, Keyur P. Patel, Ioannis Aifantis, A. Quaglieri, Shaun Fleming, Courtney D. DiNardo, Zhen Xu, Andrew W. Roberts, Marina Konopleva, Nik Cummings, Qi Zhang, Andrew H. Wei, Steve Kornblau, Chong Chyn Chua, Christina Glytsou
Publikováno v:
Blood. 135:791-803
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based com
Autor:
Andrew M. Evens, Paul M. Barr, Ann S. LaCasce, Sonali M. Smith, Michael V. Knopp, John P. Leonard, Deborah M. Stephens, David J. Straus, Hongli Li, Michael LeBlanc, Lisa M. Rimsza, Craig H. Moskowitz, Brad S. Kahl, Jonathan W. Friedberg, Heiko Schöder, Eric D. Hsi, Nancy L. Bartlett
Publikováno v:
J Nucl Med
Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography (PET)-adapted therapy on S0816 (NCT00822120). Patients received 2 cycles of doxorubicin, ble
Autor:
Stephan Stilgenbauer, Lang Zhou, Su Young Kim, Shuo Ma, Michael Hallek, Kathryn Humphrey, Barbara Eichhorst, Brenda Chyla, Andrew W. Roberts, John C. Byrd, Steven Coutre, John F. Seymour, Thomas J. Kipps, Jalaja Potluri, Matthew S. Davids, William G. Wierda, Maria Verdugo, Jacqueline Nielsen
Publikováno v:
Blood. 134:111-122
To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enro
Autor:
Jacqueline C. Barrientos, Susan O'Brien, Ulrich Jaeger, Nishitha Reddy, Jennifer R. Brown, Steven Coutre, Constantine S. Tam, Peter Hillmen, Danelle F. James, John C. Byrd, Richard R. Furman, John M. Pagel, Patrick Thornton, Remus Vezan, Paul M. Barr, Jan A. Burger, Sandra Dai, Jennifer A. Woyach, Carol Moreno, Thomas J. Kipps, Stephen P. Mulligan, Marco Montillo
Publikováno v:
Blood
BLOOD
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
BLOOD
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL). The phase 3 RESONATE trial, which compared single-agent ibrutinib to ofatumumab in high-risk, relaps
Autor:
Philippe Moreau, Artur Jurczyszyn, Bruno Paiva, Zandra Klippel, Meletios A. Dimopoulos, Ludek Pour, Ruben Niesvizky, Muhtarjan Osman, Roman Hájek, Jesús F. San-Miguel, Anita Zahlten-Kumeli, Lugui Qiu, Jae Hoon Lee, Thierry Facon
Publikováno v:
Blood. 133:1953-1963
The phase 3 CLARION study compared carfilzomib-melphalan-prednisone (KMP) with bortezomib-melphalan-prednisone (VMP) in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. Patients were randomized 1:1 to KMP or VMP for nine 42-day
Autor:
Lu Zhang, Zhi-yuan Li, Daobin Zhou, Xinxin Cao, David C. Fajgenbaum, Jian Li, Minghui Duan, Ai-lin Zhao, Jun Feng, Ding-rong Zhong
Publikováno v:
Blood. 133:1720-1728
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder. The anti–interleukin 6 (IL-6) therapy siltuximab is not available everywhere, and is not effective for over one-half of patients. Alternative treatment approac